Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:CFLAR-XRCC5

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: CFLAR-XRCC5
	FusionPDB ID: 16149
	FusionGDB2.0 ID: 16149
		Hgene	Tgene
	Gene symbol	CFLAR	XRCC5
	Gene ID	8837	7520
	Gene name	CASP8 and FADD like apoptosis regulator	X-ray repair cross complementing 5
	Synonyms	CASH\|CASP8AP1\|CLARP\|Casper\|FLAME\|FLAME-1\|FLAME1\|FLIP\|I-FLICE\|MRIT\|c-FLIP\|c-FLIPL\|c-FLIPR\|c-FLIPS\|cFLIP	KARP-1\|KARP1\|KU80\|KUB2\|Ku86\|NFIV
	Cytomap	2q33.1	2q35
	Type of gene	protein-coding	protein-coding
	Description	CASP8 and FADD-like apoptosis regulatorFADD-like antiapoptotic molecule 1MACH-related inducer of toxicitycaspase homologcaspase-eight-related proteincaspase-like apoptosis regulatory proteincaspase-related inducer of apoptosiscellular FLICE-like in	X-ray repair cross-complementing protein 586 kDa subunit of Ku antigenATP-dependent DNA helicase 2 subunit 2ATP-dependent DNA helicase II 80 kDa subunitCTC box-binding factor 85 kDa subunitCTC85CTCBFDNA repair protein XRCC5Ku autoantigen, 80kDaKu
	Modification date	20200322	20200313
	UniProtAcc	O15519 Main function of 5'-partner protein: FUNCTION: Apoptosis regulator protein which may function as a crucial link between cell survival and cell death pathways in mammalian cells. Acts as an inhibitor of TNFRSF6 mediated apoptosis. A proteolytic fragment (p43) is likely retained in the death-inducing signaling complex (DISC) thereby blocking further recruitment and processing of caspase-8 at the complex. Full length and shorter isoforms have been shown either to induce apoptosis or to reduce TNFRSF-triggered apoptosis. Lacks enzymatic (caspase) activity. {ECO:0000269\|PubMed:9880531}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000309955, ENST00000340870, ENST00000341222, ENST00000341582, ENST00000342795, ENST00000355558, ENST00000395148, ENST00000423241, ENST00000440180, ENST00000443227, ENST00000457277, ENST00000479953, ENST00000494258, ENST00000490965,	ENST00000471649, ENST00000392132, ENST00000392133,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	9 X 10 X 9=810	9 X 6 X 5=270
	# samples	12	10
	** MAII score	log2(12/810*10)=-2.75488750216347 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(10/270*10)=-1.43295940727611 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: CFLAR [Title/Abstract] AND XRCC5 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: CFLAR [Title/Abstract] AND XRCC5 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	CFLAR(202000830)-XRCC5(217054948), # samples:1
Anticipated loss of major functional domain due to fusion event.	CFLAR-XRCC5 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CFLAR-XRCC5 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CFLAR-XRCC5 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. CFLAR-XRCC5 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	CFLAR	GO:0060544	regulation of necroptotic process	21737330
Hgene	CFLAR	GO:1902042	negative regulation of extrinsic apoptotic signaling pathway via death domain receptors	26582200
Hgene	CFLAR	GO:2001237	negative regulation of extrinsic apoptotic signaling pathway	9208847
Tgene	XRCC5	GO:0002218	activation of innate immune response	28712728
Tgene	XRCC5	GO:0006303	double-strand break repair via nonhomologous end joining	26359349
Tgene	XRCC5	GO:0045860	positive regulation of protein kinase activity	22504299
Tgene	XRCC5	GO:0071480	cellular response to gamma radiation	26359349

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:202000830/chr2:217054948)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across CFLAR (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across XRCC5 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000309955	CFLAR	chr2	202000830	+	ENST00000392133	XRCC5	chr2	217054948	+	2504	1038	515	1402	295
ENST00000309955	CFLAR	chr2	202000830	+	ENST00000392132	XRCC5	chr2	217054948	+	2492	1038	515	1402	295
ENST00000443227	CFLAR	chr2	202000830	+	ENST00000392133	XRCC5	chr2	217054948	+	2036	570	251	934	227
ENST00000443227	CFLAR	chr2	202000830	+	ENST00000392132	XRCC5	chr2	217054948	+	2024	570	251	934	227
ENST00000341222	CFLAR	chr2	202000830	+	ENST00000392133	XRCC5	chr2	217054948	+	2441	975	452	1339	295
ENST00000341222	CFLAR	chr2	202000830	+	ENST00000392132	XRCC5	chr2	217054948	+	2429	975	452	1339	295
ENST00000340870	CFLAR	chr2	202000830	+	ENST00000392133	XRCC5	chr2	217054948	+	2441	975	452	1339	295
ENST00000340870	CFLAR	chr2	202000830	+	ENST00000392132	XRCC5	chr2	217054948	+	2429	975	452	1339	295
ENST00000355558	CFLAR	chr2	202000830	+	ENST00000392133	XRCC5	chr2	217054948	+	2441	975	452	1339	295
ENST00000355558	CFLAR	chr2	202000830	+	ENST00000392132	XRCC5	chr2	217054948	+	2429	975	452	1339	295
ENST00000341582	CFLAR	chr2	202000830	+	ENST00000392133	XRCC5	chr2	217054948	+	2401	935	412	1299	295
ENST00000341582	CFLAR	chr2	202000830	+	ENST00000392132	XRCC5	chr2	217054948	+	2389	935	412	1299	295
ENST00000342795	CFLAR	chr2	202000830	+	ENST00000392133	XRCC5	chr2	217054948	+	2369	903	380	1267	295
ENST00000342795	CFLAR	chr2	202000830	+	ENST00000392132	XRCC5	chr2	217054948	+	2357	903	380	1267	295
ENST00000395148	CFLAR	chr2	202000830	+	ENST00000392133	XRCC5	chr2	217054948	+	2201	735	212	1099	295
ENST00000395148	CFLAR	chr2	202000830	+	ENST00000392132	XRCC5	chr2	217054948	+	2189	735	212	1099	295
ENST00000423241	CFLAR	chr2	202000830	+	ENST00000392133	XRCC5	chr2	217054948	+	2537	1071	548	1435	295
ENST00000423241	CFLAR	chr2	202000830	+	ENST00000392132	XRCC5	chr2	217054948	+	2525	1071	548	1435	295
ENST00000440180	CFLAR	chr2	202000830	+	ENST00000392133	XRCC5	chr2	217054948	+	2352	886	363	1250	295
ENST00000440180	CFLAR	chr2	202000830	+	ENST00000392132	XRCC5	chr2	217054948	+	2340	886	363	1250	295
ENST00000457277	CFLAR	chr2	202000830	+	ENST00000392133	XRCC5	chr2	217054948	+	1989	523	0	887	295
ENST00000457277	CFLAR	chr2	202000830	+	ENST00000392132	XRCC5	chr2	217054948	+	1977	523	0	887	295
ENST00000494258	CFLAR	chr2	202000830	+	ENST00000392133	XRCC5	chr2	217054948	+	1780	314	67	678	203
ENST00000494258	CFLAR	chr2	202000830	+	ENST00000392132	XRCC5	chr2	217054948	+	1768	314	67	678	203
ENST00000479953	CFLAR	chr2	202000830	+	ENST00000392133	XRCC5	chr2	217054948	+	1753	287	34	651	205
ENST00000479953	CFLAR	chr2	202000830	+	ENST00000392132	XRCC5	chr2	217054948	+	1741	287	34	651	205

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000309955	ENST00000392133	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000303407	0.9996966
ENST00000309955	ENST00000392132	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000301244	0.99969876
ENST00000443227	ENST00000392133	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.001007622	0.9989924
ENST00000443227	ENST00000392132	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000997445	0.9990025
ENST00000341222	ENST00000392133	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000342877	0.99965715
ENST00000341222	ENST00000392132	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000340357	0.99965966
ENST00000340870	ENST00000392133	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000342877	0.99965715
ENST00000340870	ENST00000392132	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000340357	0.99965966
ENST00000355558	ENST00000392133	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000342877	0.99965715
ENST00000355558	ENST00000392132	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000340357	0.99965966
ENST00000341582	ENST00000392133	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000297536	0.9997024
ENST00000341582	ENST00000392132	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000293854	0.9997061
ENST00000342795	ENST00000392133	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000255701	0.99974424
ENST00000342795	ENST00000392132	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000254314	0.99974567
ENST00000395148	ENST00000392133	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000253955	0.999746
ENST00000395148	ENST00000392132	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.00024961	0.99975044
ENST00000423241	ENST00000392133	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000282776	0.9997172
ENST00000423241	ENST00000392132	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.00028035	0.9997197
ENST00000440180	ENST00000392133	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000244016	0.99975604
ENST00000440180	ENST00000392132	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000240411	0.9997596
ENST00000457277	ENST00000392133	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000221229	0.9997788
ENST00000457277	ENST00000392132	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000217045	0.999783
ENST00000494258	ENST00000392133	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000616191	0.9993838
ENST00000494258	ENST00000392132	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000592773	0.9994073
ENST00000479953	ENST00000392133	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000780807	0.9992192
ENST00000479953	ENST00000392132	CFLAR	chr2	202000830	+	XRCC5	chr2	217054948	+	0.000746472	0.99925345

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CFLAR-XRCC5

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
CFLAR	chr2	202000830	XRCC5	chr2	217054948	1038	174	IDLKTKIQKYKQSASNQLINHIEQFL
CFLAR	chr2	202000830	XRCC5	chr2	217054948	1071	174	IDLKTKIQKYKQSASNQLINHIEQFL
CFLAR	chr2	202000830	XRCC5	chr2	217054948	287	84	IDLKTKIQKYKQSASNQLINHIEQFL
CFLAR	chr2	202000830	XRCC5	chr2	217054948	314	82	IDLKTKIQKYKQSASNQLINHIEQFL
CFLAR	chr2	202000830	XRCC5	chr2	217054948	523	174	IDLKTKIQKYKQSASNQLINHIEQFL
CFLAR	chr2	202000830	XRCC5	chr2	217054948	570	106	IDLKTKIQKYKQSASNQLINHIEQFL
CFLAR	chr2	202000830	XRCC5	chr2	217054948	735	174	IDLKTKIQKYKQSASNQLINHIEQFL
CFLAR	chr2	202000830	XRCC5	chr2	217054948	886	174	IDLKTKIQKYKQSASNQLINHIEQFL
CFLAR	chr2	202000830	XRCC5	chr2	217054948	903	174	IDLKTKIQKYKQSASNQLINHIEQFL
CFLAR	chr2	202000830	XRCC5	chr2	217054948	935	174	IDLKTKIQKYKQSASNQLINHIEQFL
CFLAR	chr2	202000830	XRCC5	chr2	217054948	975	174	IDLKTKIQKYKQSASNQLINHIEQFL

Top

Potential FusionNeoAntigen Information of CFLAR-XRCC5 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

CFLAR-XRCC5_202000830_217054948.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B48:01	KQSASNQL	0.9954	0.514	10	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B08:09	IQKYKQSA	0.9864	0.5216	6	14
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B39:13	KQSASNQL	0.7855	0.8901	10	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B39:01	YKQSASNQL	0.9967	0.8688	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B14:02	YKQSASNQL	0.9934	0.6088	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B14:01	YKQSASNQL	0.9934	0.6088	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B39:13	YKQSASNQL	0.9924	0.8992	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B38:01	YKQSASNQL	0.99	0.929	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B38:02	YKQSASNQL	0.989	0.9404	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B15:10	YKQSASNQL	0.9275	0.5569	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B15:18	YKQSASNQL	0.7149	0.715	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B13:02	KQSASNQLI	0.6937	0.7277	10	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B15:03	YKQSASNQL	0.6572	0.7458	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B15:37	YKQSASNQL	0.5138	0.6035	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B13:01	KQSASNQLI	0.5053	0.9752	10	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B39:13	KQSASNQLI	0.2416	0.8149	10	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B52:01	KQSASNQLI	0.0234	0.9564	10	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B39:08	KQSASNQL	0.8514	0.7547	10	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B39:09	YKQSASNQL	0.998	0.5906	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B39:12	YKQSASNQL	0.9947	0.8731	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B39:05	YKQSASNQL	0.9924	0.8435	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-C07:29	YKQSASNQL	0.9698	0.9158	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-C07:13	YKQSASNQL	0.9673	0.914	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B39:08	YKQSASNQL	0.76	0.7119	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B14:03	YKQSASNQL	0.4201	0.6488	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B39:08	KQSASNQLI	0.3238	0.7158	10	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-C12:16	YKQSASNQL	0.1624	0.9461	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B39:02	KQSASNQL	0.9212	0.8937	10	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B39:31	YKQSASNQL	0.9969	0.8701	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B39:02	YKQSASNQL	0.9965	0.9026	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B38:05	YKQSASNQL	0.99	0.929	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-C07:17	YKQSASNQL	0.957	0.9572	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B15:09	YKQSASNQL	0.8733	0.6923	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-C07:22	YKQSASNQL	0.8682	0.6611	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B39:11	YKQSASNQL	0.7949	0.6361	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-C07:04	YKQSASNQL	0.7699	0.9103	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B15:73	KQSASNQLI	0.7358	0.8744	10	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-C03:67	YKQSASNQL	0.7267	0.9748	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B48:02	YKQSASNQL	0.6619	0.9212	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B15:30	KQSASNQLI	0.5922	0.7951	10	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-C06:08	YKQSASNQL	0.5534	0.9828	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-C06:06	YKQSASNQL	0.4087	0.9813	9	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B39:02	KQSASNQLI	0.2894	0.8229	10	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	HLA-B15:54	YKQSASNQL	0.1068	0.8069	9	18

Top

Potential FusionNeoAntigen Information of CFLAR-XRCC5 in HLA II

CFLAR-XRCC5_202000830_217054948.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0103	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0109	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0113	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0113	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0115	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0117	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0117	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0121	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0121	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0469	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0469	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0469	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0469	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0482	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0482	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0701	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0701	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0701	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0701	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0701	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0703	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0703	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0703	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0703	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0703	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0704	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0704	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0704	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0704	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0704	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0705	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0705	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0705	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0705	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0705	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0706	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0706	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0706	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0706	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0706	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0707	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0707	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0707	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0707	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0707	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0708	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0708	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0708	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0708	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0708	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0709	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0709	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0709	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0709	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0709	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0711	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0711	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0711	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0711	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0711	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0712	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0712	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0712	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0712	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0712	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0713	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0713	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0713	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0713	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0713	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0714	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0714	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0714	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0714	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0714	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0715	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0715	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0715	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0715	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0715	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0716	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0716	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0716	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0716	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0716	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0717	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0717	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0717	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0717	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0717	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0719	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0719	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0719	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0719	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0719	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0819	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0825	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0901	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0901	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0901	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0901	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0901	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0902	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0902	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0902	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0902	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0903	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0903	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0903	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0903	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0904	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0904	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0904	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0904	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0904	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0905	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0905	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0905	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0905	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0907	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0907	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0907	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0907	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0907	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0908	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0908	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0908	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0908	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0909	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0909	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0909	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0909	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-0909	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1407	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1407	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1448	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1468	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1468	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1468	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1493	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1493	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1493	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1503	LKTKIQKYKQSASNQ	2	17
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1503	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1504	LKTKIQKYKQSASNQ	2	17
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1510	LKTKIQKYKQSASNQ	2	17
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1510	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1511	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1511	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1515	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1518	LKTKIQKYKQSASNQ	2	17
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1518	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1523	LKTKIQKYKQSASNQ	2	17
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1523	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1527	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1527	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1528	LKTKIQKYKQSASNQ	2	17
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1528	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1529	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1529	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1531	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1534	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1534	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1534	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1535	LKTKIQKYKQSASNQ	2	17
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1535	KTKIQKYKQSASNQL	3	18
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1537	LKTKIQKYKQSASNQ	2	17
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1601	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1601	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1602	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1602	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1602	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1603	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1603	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1604	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1604	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1605	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1605	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1607	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1607	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1608	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1608	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1610	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1611	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1611	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1611	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1612	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1612	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1612	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1614	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1614	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1614	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1616	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1616	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB1-1616	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB3-0109	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB3-0205	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB3-0209	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB3-0209	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB3-0212	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB3-0215	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB3-0215	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB3-0216	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB3-0216	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB3-0221	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB3-0221	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB3-0303	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB3-0303	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB5-0112	IQKYKQSASNQLINH	6	21
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB5-0112	KIQKYKQSASNQLIN	5	20
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB5-0112	QKYKQSASNQLINHI	7	22
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB5-0112	TKIQKYKQSASNQLI	4	19
CFLAR-XRCC5	chr2	202000830	chr2	217054948	1038	DRB5-0204	LKTKIQKYKQSASNQ	2	17

Top

Fusion breakpoint peptide structures of CFLAR-XRCC5

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
3920	IQKYKQSASNQLIN	CFLAR	XRCC5	chr2	202000830	chr2	217054948	1038

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CFLAR-XRCC5

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	3920	IQKYKQSASNQLIN	-7.32363	-7.43703
HLA-B14:02	3BVN	3920	IQKYKQSASNQLIN	-5.12986	-6.16516
HLA-B52:01	3W39	3920	IQKYKQSASNQLIN	-6.16001	-6.27341
HLA-B52:01	3W39	3920	IQKYKQSASNQLIN	-5.89891	-6.93421
HLA-A11:01	4UQ2	3920	IQKYKQSASNQLIN	10000.1	10000
HLA-A24:02	5HGA	3920	IQKYKQSASNQLIN	-7.35926	-7.47266
HLA-A24:02	5HGA	3920	IQKYKQSASNQLIN	-5.77242	-6.80772
HLA-B27:05	6PYJ	3920	IQKYKQSASNQLIN	-7.95098	-8.06438
HLA-B44:05	3DX8	3920	IQKYKQSASNQLIN	-5.98793	-7.02323
HLA-B44:05	3DX8	3920	IQKYKQSASNQLIN	-5.90989	-6.02329
HLA-A02:01	6TDR	3920	IQKYKQSASNQLIN	-5.68921	-6.72451

Top

Vaccine Design for the FusionNeoAntigens of CFLAR-XRCC5

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
CFLAR-XRCC5	chr2	202000830	chr2	217054948	10	18	KQSASNQL	AGCAGTCTGCGAGTAACCAGCTCA
CFLAR-XRCC5	chr2	202000830	chr2	217054948	10	19	KQSASNQLI	AGCAGTCTGCGAGTAACCAGCTCATAA
CFLAR-XRCC5	chr2	202000830	chr2	217054948	6	14	IQKYKQSA	TCCAGAAGTACAAGCAGTCTGCGA
CFLAR-XRCC5	chr2	202000830	chr2	217054948	9	18	YKQSASNQL	ACAAGCAGTCTGCGAGTAACCAGCTCA

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
CFLAR-XRCC5	chr2	202000830	chr2	217054948	2	17	LKTKIQKYKQSASNQ	TGAAGACAAAAATCCAGAAGTACAAGCAGTCTGCGAGTAACCAGC
CFLAR-XRCC5	chr2	202000830	chr2	217054948	3	18	KTKIQKYKQSASNQL	AGACAAAAATCCAGAAGTACAAGCAGTCTGCGAGTAACCAGCTCA
CFLAR-XRCC5	chr2	202000830	chr2	217054948	4	19	TKIQKYKQSASNQLI	CAAAAATCCAGAAGTACAAGCAGTCTGCGAGTAACCAGCTCATAA
CFLAR-XRCC5	chr2	202000830	chr2	217054948	5	20	KIQKYKQSASNQLIN	AAATCCAGAAGTACAAGCAGTCTGCGAGTAACCAGCTCATAAATC
CFLAR-XRCC5	chr2	202000830	chr2	217054948	6	21	IQKYKQSASNQLINH	TCCAGAAGTACAAGCAGTCTGCGAGTAACCAGCTCATAAATCACA
CFLAR-XRCC5	chr2	202000830	chr2	217054948	7	22	QKYKQSASNQLINHI	AGAAGTACAAGCAGTCTGCGAGTAACCAGCTCATAAATCACATCG

Top

Information of the samples that have these potential fusion neoantigens of CFLAR-XRCC5

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
UCEC	CFLAR-XRCC5	chr2	202000830	ENST00000309955	chr2	217054948	ENST00000392132	TCGA-JU-AAVI-01A

Top

Potential target of CAR-T therapy development for CFLAR-XRCC5

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to CFLAR-XRCC5

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to CFLAR-XRCC5

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)